Cannabis Law Report

MARCH 19, 2020

hemp farmers are denied profitable markets for their crops, while unregulated products continue to proliferate, with no safeguards for public health and safety. With regard to adding CBD to food and beverages, FDA maintains that the data currently available raises safety concerns and encourages parties to share relevant information with FDA.

Hemp 64

Hemp CBD Safety Topical 64

Cannabis Law Report

MARCH 7, 2020

hemp farmers are denied profitable markets for their crops, while unregulated products continue to proliferate, with no safeguards for public health and safety. With regard to adding CBD to food and beverages, FDA maintains that the data currently available raises safety concerns and encourages parties to share relevant information with FDA.

Hemp 71

Hemp CBD Research and Development Safety 71

Cannabis Law Report

NOVEMBER 26, 2019

The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. This includes ongoing work to obtain and evaluate information to address outstanding questions related to the safety of CBD products, while maintaining the agency’s rigorous public health standards.

Safety 64

Safety Food CBD Oil 64

Canna Law Blog

APRIL 13, 2019

Marketing, labeling and sales : How should consumers be informed about the risks associated with such products (e.g., What specific risks should consumers be informed about? For a complete list of questions and topics identified by the FDA, see here. directions for use, warnings)?

CBD 93

CBD Safety Topical Food 93

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. For more information, visit www.inmedpharma.com. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

SEPTEMBER 1, 2021

WORCESTER —On the eve of Wednesday, September 1, the Cannabis Control Commission (Commission)’s fourth birthday, adult-use Marijuana Establishments in Massachusetts surpassed $2 billion in gross sales , according to information reported in the state’s mandatory seed-to-sale tracking system, the agency announced today.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Cannabis Law Report

AUGUST 11, 2021

A replay will be available from the Investor Relations section of HempFusion’s website at HempFusion.com/corporate-information. Use Entry Code: 746381. To join the webcast, please visit [link]. ABOUT HEMPFUSION. HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.

Research and Development 105

Research and Development Tincture Food Hemp 105

Cannabis Law Report

FEBRUARY 13, 2022

The Program Specialist 2 (Cannabis) positions will perform applicant and licensee inspection of physical facilities, adherence to program regulations, development of guidance documents and statement of findings and other duties ensuring licensees are complying with public health and safety best practices.

Programs 52

Programs Research and Development Seed-To-Sale Compliance 52

Canna Law Blog

JULY 25, 2019

In response to Senator Wyden and other stakeholders’ demands, FDA Acting Chief Information Officer, Amy Abernethy, recently announced on Twitter that: [FDA] is expediting its work to address the many questions about cannabidiol (CBD). Four days before the deadline, over three thousand comments had been published on the public docket.

CBD 98

CBD Research and Development Hemp Food 98

Cannabis Law Report

JULY 8, 2021

The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. and are difficult to predict. cbdMD, Inc. John Weston.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

NOVEMBER 24, 2019

Building the bridge between brands and the marketplace through testing and the importance of good data. These events, amongst other drivers, have shown the obvious need to regulate product safety in CBD and THC products in a holistic and standardized way. Shannon Swantek, CQA, Principal Scientist, CEO, Enlightened Quality Analytics.

Business 95

Business Data Wellness and Beauty Safety 95

The Cannigma

DECEMBER 20, 2021

These methods may include: regular consumption inhalation oral administration local treatment via topical products. The results were very positive and showed the safety and effectiveness of the topical CBD. The interaction of cannabis with acne has quite limited medical data and there are few conflicting hypotheses.

Terpenes 133

Terpenes Cannabinoids Topical Research and Development 133

Canna Law Blog

AUGUST 19, 2020

It happens more often than you might think depending on the topic (see, for example, the NLRB ). To date, it’s truly been “buyer beware” outside of states putting together their own protocols on things like recalls, packaging and labeling safety standards, quality assurance reviews, and testing.

Pets 71

Pets Safety Packaging CBD 71

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

AUGUST 3, 2021

Mainly, the measure protects patient safety and amplifies product quality requirements, all the while entrusting the state’s Medical Marijuana Advisory Board to consider broadening the program’s list of qualifying medical conditions. Yeast and mold are two examples of contaminants that are commonly found in cannabis products. .

Legislation 98

Legislation Patients Supply Chain Dispensary 98

MMJ Recs

MARCH 16, 2024

Recent trends indicate a growing interest in alternative forms of consumption, such as edibles, topicals, and concentrates, in addition to traditional flower products. Regulations vary significantly by jurisdiction but typically encompass licensing requirements, product safety standards, and distribution protocols.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

SEPTEMBER 29, 2021

With patient safety at the center of its mission, TCI was created to educate healthcare professionals on the risks and benefits of medical cannabis, now legal in the state of New York and beyond.

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Cannabis Law Report

OCTOBER 21, 2021

adults shows broad support for securely labeling cannabis products to verify their legitimacy and safety in the marketplace. Ensuring the safety of cannabis products is top of mind for Americans.

Safety 52

Safety Research and Development Compliance Compliance 52

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is collecting data to fill these gaps. The public hearing attracted over 100 speakers and 2000 participants. What’s Next?

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

JUNE 3, 2022

technology, clinical protocol, human-interaction psychology, and data science? enhance the safety and efficacy of our compounds.? . ** We are looking for this position to be based out of NYC or Boston. work on a wide range of topics?? . in order to ?enhance Berlin is ok too. Opportunity: . Advanced degree (Ph.D.

Environment 52

Environment Topical Data Safety 52

Cannabis Law Report

MARCH 1, 2022

technology, clinical protocol, human-interaction psychology, and data science? enhance the safety and efficacy of our compounds.? . ** We are looking for this position to be based out of NYC or Boston. work on a wide range of topics?? . in order to ?enhance Berlin is ok too. Opportunity: . Advanced degree (Ph.D.

Environment 40

Environment Topical Data Safety 40

Cannabis Law Report

MARCH 19, 2020

2 At the conclusion of the meeting, FDA stated that it would form an internal working group to study data gaps relating to CBD. As indicated by FDA’s recent announcement, the collection of data about the risks and benefits of CBD remains a priority for the agency. FDA submitted this report last week, as is discussed below.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. For more information, visit www.inmedpharma.com. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 3, 2021

In addition to FDM and e-commerce, the Transaction provides added distribution channels, increasing HempFusion’s 5 channel strategy to 6 channels and bolstering topical product distribution sales. Robust eCommerce platform drives over 17,000 average monthly sessions, and nearly $2.0 Chief Executive Officer of HempFusion. “We

Research and Development 105

Research and Development Topical Compliance Compliance 105

Cannabis Law Report

JANUARY 12, 2022

In accordance with FDA requirements, an independent panel of qualified experts reviewed HempFusion’s safety dossier on its hemp-derived CBD extract, which included safety and toxicology studies, the published results of these studies, and a comprehensive review of the scientific literature on CBD. HempFusion Wellness Inc.

Retail 52

Retail CBD Extraction Research and Development 52

Cannabis Law Report

JUNE 1, 2021

All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Martha Stewart CBD products are already a top 9 brand among all CBD supplements in the food, drug and convenience-store channel, according to IRI data for the 4 weeks ended April 18, 2021. Net revenue.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”.

THC 52

THC CBD Media Food 52

WeedAdvisor

JULY 9, 2019

But now, a larger-scale, nationwide study published by Jama Pediatrics has more recent data, covers a broader timeframe and uses a massive sample size. Specifically, it took data from surveys dating between 1993 and 2017, including data from 1.4 Up until now, studies into this topic were contradictory. Absolutely.

Legalization 61

Legalization Data Recreational Legislation 61

Cannabis Law Report

AUGUST 27, 2021

Built on a foundation of regulatory compliance and human safety, HempFusion Wellness offers a diverse product portfolio comprising of over 75 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. HempFusion Wellness Inc. FORWARD-LOOKING STATEMENTS.

Research and Development 105

Research and Development Events Hemp Food 105

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., CBD is marketed in a variety of product types, such as oil drops, capsules, syrups, teas and topical lotions and creams.

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

AUGUST 25, 2021

The #1 brand in CBD topicals, with 23% market share in the Drug channel [Drug (IRI-SPINScan 52 week ending 7-11-2021)] and 13.8-per-cent HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Retail 111

Retail Supply Chain Research and Development Events 111

Cannabis Law Report

APRIL 22, 2019

In this largely unregulated market, this first public comment action seems to be a genuine effort to allow the hemp industry to weigh in, so that the FDA would even have the necessary information to issue an NPRM. Also: Are there any currently used standardized definitions for the ingredients in cannabis products (e.g., hemp oil”)?

Hemp 56

Hemp Compliance Compliance CBD 56

Canna Law Blog

JUNE 5, 2019

The objective of the meeting was to gather scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of these products. Accordingly, CBD cannot be marketed simultaneously as a food/dietary supplement and a drug.u. PROPONENTS AND OPPONENTS.

CBD 56

CBD Hemp Food Agriculture 56

Medicinal Genomics

SEPTEMBER 27, 2018

In addition, we’ve written a substantial review of this topic in a document prepared for the United States Pharmacopeia. We have worked closely with Chris over the years, and ironically, co-authored a manuscript on this very topic with him. We feel a comprehensive rebuttal is the most transparent approach to such a complicated topic.

Food 69

Food Data Safety Patients 69

Cannabis Law Report

FEBRUARY 3, 2022

The introduction of keynotes speakers, which are free to attend for all event participants, supports the industry’s need for high-level education and forward-looking insights addressing timely topics such as collaborative robotics in the workforce and supply chain challenges. Health and Safety. About Informa Markets.

Packaging 52

Packaging Events Education Supply Chain 52

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). One of the leading cannabis clinicians in the U.S.,

CBD 122

CBD Research and Development Epilepsy Extraction 122

NORML

MAY 24, 2019

Safeguarding safety and public health through advertising restrictions, stringent quality control, harm reduction options, and public education. If you would like more information about this topic, please contact Mary Kruger at 585-469-6731 , or email at rocnorml@rocnorml.org. percent to 17.8 percent in 2016.

Marijuana 103

Marijuana Education Advocacy Legislation 103